Case Report: Relapsing systemic lupus erythematosus treated with dual rituximab and anifrolumab therapy.

ABSTRACT: While biologic monotherapy is commonly used in the management of moderate-to-severe systemic lupus erythematosus (SLE), limited data exists regarding the efficacy and safety of dual biologic therapy in SLE. We report the case of a 42-year-old woman with a history of SLE complicated by Rowell Syndrome (RS) that was managed on anifrolumab and a recent diagnosis of moyamoya disease, who presented with new-onset lower extremity weakness. Laboratory testing was notable for active lupus serologies, and magnetic resonance angiography (MRA) findings were consistent with worsening moyamoya syndrome. Given the clinical and radiographic findings, a diagnosis of CNS lupus was suspected. Anifrolumab was discontinued and she was started on pulse dose corticosteroids and rituximab, resulting in marked ne

SUBMITTER: Lee S 

PROVIDER: S-EPMC12816201 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature